{"id":2175,"url":"\/distributions\/2175\/click?bit=1&hash=803b6e1bcbd9dfc4ba9456fda887a878c80d24df8d3a575913b14876e18923a5","title":"TJ \u0437\u0430\u043a\u0440\u043e\u0435\u0442\u0441\u044f 10 \u0441\u0435\u043d\u0442\u044f\u0431\u0440\u044f \u2014\u00a0\u043f\u0440\u043e\u0447\u0438\u0442\u0430\u0439\u0442\u0435 \u0430\u043d\u043e\u043d\u0441 \u0441 \u0434\u0435\u0442\u0430\u043b\u044f\u043c\u0438","buttonText":"\u0427\u0438\u0442\u0430\u0442\u044c","imageUuid":"d1d355d8-93a3-5140-aeae-14b03046b760","isPaidAndBannersEnabled":false}
Офтоп
Pramod

Immunotherapy Drugs Market Share Assessments for the Regional and Country Level Segments

Health care for people living in the immunotherapy, leading to dominate the end-user segment.

The United States of America - the largest immunotherapy market in the United States of America in 2017. The Contribution of the United States of America. , Rising Prevalence of Growth Diseases, and Growing presence of market players in the region. Furthermore, factors such as research and development (R & D) and companies will also be supported.

Some diseases are under clinical trials. Thus, increasing the rate of market demand. Moreover, they are not a factor in the development of the immunotherapy drugs market.

The report provides epidemiology analysis for cancer, autoimmune and inflammatory diseases, and infectious diseases. According to the International Agency for Research on Cancer (IARC) in 2018, 18.1 million people were estimated to be 29.5 million by 2040. –2015, reported during this period, of which 16.4% were due

Similarly, in April 2018, Pfizer Inc. and Allogene Therapeutics Inc. Pfizer? Pfizer Inc. to continue the development of CAR-T therapy.

Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson Johnson Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly & Company, Sanofi, Medigene AG, CH Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, and Celgene Corporation.

0
Комментарии
Читать все 0 комментариев
null